Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease

Bun Yamagata, Takuya Watanabe, Hiroi Tomioka, Hitomi Kobayashi, Yasuko Nakano, Masaru Mimura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Treatment with donepezil (maximum dose, 10. mg/day) was recently approved in Japan for severe Alzheimer's disease (AD). We examined the usefulness of serum insulin-like growth factor-I (IGF-I) level as a biomarker for predicting responders to 10. mg/day-donepezil treatment among mild-to-moderate AD patients. The study population consisted of 23 mild-to-moderate AD patients, who were non-responders to 5. mg/day-donepezil treatment. AD patients were divided into responders and non-responders based on changes in mini-mental state examination (MMSE) scores before and 12. weeks after increasing donepezil dose from 5 to 10. mg/day. Before increasing donepezil dose, based on serum IGF-I levels and MMSE scores positively correlated with each other, AD patients were classified into three groups. Group A (n=6) had IGF-I ≤99ng/mL and MMSE ≤18, group B (n=9) had IGF-I ≤99 ng/mL and MMSE >18, and group C (n=8) had IGF-I >99 ng/mL and MMSE > 18. Serum IGF-I levels were significantly lower in groups A and B than group C. After 10. mg/day-donepezil treatment, the mean MMSE improved significantly only in group A. The prevalence of responders to the treatment was markedly greater in group A than in groups B and C. These results suggested that decreased serum IGF-I level combined with low MMSE score may be a useful biomarker for predicting responders to 10. mg/day-donepezil treatment in mild-to-moderate AD patients exhibiting a poor response to 5. mg/day-donepezil treatment.

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalRegulatory Peptides
Volume163
Issue number1-3
DOIs
Publication statusPublished - 2010 Aug
Externally publishedYes

Fingerprint

Biomarkers
Insulin-Like Growth Factor I
Sorting
Alzheimer Disease
Serum
Therapeutics
donepezil
Japan
Population

Keywords

  • Alzheimer's disease
  • Cognitive function
  • Donepezil
  • Insulin-like growth factor-I
  • Responder

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease. / Yamagata, Bun; Watanabe, Takuya; Tomioka, Hiroi; Kobayashi, Hitomi; Nakano, Yasuko; Mimura, Masaru.

In: Regulatory Peptides, Vol. 163, No. 1-3, 08.2010, p. 137-142.

Research output: Contribution to journalArticle

@article{bb449d1e60384526b589c7a3daa99e6d,
title = "Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease",
abstract = "Treatment with donepezil (maximum dose, 10. mg/day) was recently approved in Japan for severe Alzheimer's disease (AD). We examined the usefulness of serum insulin-like growth factor-I (IGF-I) level as a biomarker for predicting responders to 10. mg/day-donepezil treatment among mild-to-moderate AD patients. The study population consisted of 23 mild-to-moderate AD patients, who were non-responders to 5. mg/day-donepezil treatment. AD patients were divided into responders and non-responders based on changes in mini-mental state examination (MMSE) scores before and 12. weeks after increasing donepezil dose from 5 to 10. mg/day. Before increasing donepezil dose, based on serum IGF-I levels and MMSE scores positively correlated with each other, AD patients were classified into three groups. Group A (n=6) had IGF-I ≤99ng/mL and MMSE ≤18, group B (n=9) had IGF-I ≤99 ng/mL and MMSE >18, and group C (n=8) had IGF-I >99 ng/mL and MMSE > 18. Serum IGF-I levels were significantly lower in groups A and B than group C. After 10. mg/day-donepezil treatment, the mean MMSE improved significantly only in group A. The prevalence of responders to the treatment was markedly greater in group A than in groups B and C. These results suggested that decreased serum IGF-I level combined with low MMSE score may be a useful biomarker for predicting responders to 10. mg/day-donepezil treatment in mild-to-moderate AD patients exhibiting a poor response to 5. mg/day-donepezil treatment.",
keywords = "Alzheimer's disease, Cognitive function, Donepezil, Insulin-like growth factor-I, Responder",
author = "Bun Yamagata and Takuya Watanabe and Hiroi Tomioka and Hitomi Kobayashi and Yasuko Nakano and Masaru Mimura",
year = "2010",
month = "8",
doi = "10.1016/j.regpep.2010.04.010",
language = "English",
volume = "163",
pages = "137--142",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Preliminary use of insulin-like growth factor-I as a biomarker for sorting high-dose donepezil responders among Japanese patients with Alzheimer's disease

AU - Yamagata, Bun

AU - Watanabe, Takuya

AU - Tomioka, Hiroi

AU - Kobayashi, Hitomi

AU - Nakano, Yasuko

AU - Mimura, Masaru

PY - 2010/8

Y1 - 2010/8

N2 - Treatment with donepezil (maximum dose, 10. mg/day) was recently approved in Japan for severe Alzheimer's disease (AD). We examined the usefulness of serum insulin-like growth factor-I (IGF-I) level as a biomarker for predicting responders to 10. mg/day-donepezil treatment among mild-to-moderate AD patients. The study population consisted of 23 mild-to-moderate AD patients, who were non-responders to 5. mg/day-donepezil treatment. AD patients were divided into responders and non-responders based on changes in mini-mental state examination (MMSE) scores before and 12. weeks after increasing donepezil dose from 5 to 10. mg/day. Before increasing donepezil dose, based on serum IGF-I levels and MMSE scores positively correlated with each other, AD patients were classified into three groups. Group A (n=6) had IGF-I ≤99ng/mL and MMSE ≤18, group B (n=9) had IGF-I ≤99 ng/mL and MMSE >18, and group C (n=8) had IGF-I >99 ng/mL and MMSE > 18. Serum IGF-I levels were significantly lower in groups A and B than group C. After 10. mg/day-donepezil treatment, the mean MMSE improved significantly only in group A. The prevalence of responders to the treatment was markedly greater in group A than in groups B and C. These results suggested that decreased serum IGF-I level combined with low MMSE score may be a useful biomarker for predicting responders to 10. mg/day-donepezil treatment in mild-to-moderate AD patients exhibiting a poor response to 5. mg/day-donepezil treatment.

AB - Treatment with donepezil (maximum dose, 10. mg/day) was recently approved in Japan for severe Alzheimer's disease (AD). We examined the usefulness of serum insulin-like growth factor-I (IGF-I) level as a biomarker for predicting responders to 10. mg/day-donepezil treatment among mild-to-moderate AD patients. The study population consisted of 23 mild-to-moderate AD patients, who were non-responders to 5. mg/day-donepezil treatment. AD patients were divided into responders and non-responders based on changes in mini-mental state examination (MMSE) scores before and 12. weeks after increasing donepezil dose from 5 to 10. mg/day. Before increasing donepezil dose, based on serum IGF-I levels and MMSE scores positively correlated with each other, AD patients were classified into three groups. Group A (n=6) had IGF-I ≤99ng/mL and MMSE ≤18, group B (n=9) had IGF-I ≤99 ng/mL and MMSE >18, and group C (n=8) had IGF-I >99 ng/mL and MMSE > 18. Serum IGF-I levels were significantly lower in groups A and B than group C. After 10. mg/day-donepezil treatment, the mean MMSE improved significantly only in group A. The prevalence of responders to the treatment was markedly greater in group A than in groups B and C. These results suggested that decreased serum IGF-I level combined with low MMSE score may be a useful biomarker for predicting responders to 10. mg/day-donepezil treatment in mild-to-moderate AD patients exhibiting a poor response to 5. mg/day-donepezil treatment.

KW - Alzheimer's disease

KW - Cognitive function

KW - Donepezil

KW - Insulin-like growth factor-I

KW - Responder

UR - http://www.scopus.com/inward/record.url?scp=77953916898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953916898&partnerID=8YFLogxK

U2 - 10.1016/j.regpep.2010.04.010

DO - 10.1016/j.regpep.2010.04.010

M3 - Article

C2 - 20451565

AN - SCOPUS:77953916898

VL - 163

SP - 137

EP - 142

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3

ER -